Primer: inflammasomes and interleukin 1β in inflammatory disorders

Fritz JH et al. (2005) How Toll-like receptors and Nod-like receptors contribute to innate immunity in mammals. J Endotoxin Res 11: 390–394

Martinon F et al. (2005) NLRs join TLRs as innate sensors of pathogens. Trends Immunol 26: 447–454

Auron PE et al. (1984) Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA 81: 7907–7911

Mandrup-Poulsen T et al. (1986) Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 29: 63–67

Martinon F et al. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237–241

Church LD et al. (2006) Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol 27: 494–508

O'Neill LA (2006) How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 18: 3–9

Anderson KV et al. (1985) Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 42: 791–798

Medzhitov R et al. (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394–397

Matzinger P (2002) The danger model: a renewed sense of self. Science 296: 301–305

Shi Y et al. (2003) Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516–521

Ting JP et al. (2006) CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 6: 183–195

Fritz JH et al. (2006) Nod-like proteins in immunity, inflammation and disease. Nat Immunol 7: 1250–1257

Mariathasan S et al. (2007) Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7: 31–40

Inohara N et al. (2003) Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 278: 5509–5512

Ogura Y et al. (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603–606

Maeda S et al. (2005) Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 307: 734–738

Tromp G et al. (1996) Genetic linkage of familial granulomatous inflammatory arthritis, skin rash, and uveitis to chromosome 16. Am J Hum Genet 59: 1097–1107

Miceli-Richard C et al. (2001) CARD15 mutations in Blau syndrome. Nat Genet 29: 19–20

van Duist MM et al. (2005) A new CARD15 mutation in Blau syndrome. Eur J Hum Genet 13: 742–747

Kanazawa N et al. (2005) Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 105: 1195–1197

Okamura H et al. (1998) Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 70: 281–312

Schmitz J et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479–490

Carriere V et al. (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104: 282–287

Agostini L et al. (2004) NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 20: 319–325

Dowds TA et al. (2004) Cryopyrin-induced interleukin 1beta secretion in monocytic cells: enhanced activity of disease-associated mutants and requirement for ASC. J Biol Chem 279: 21924–21928

Martinon F et al. (2007) Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14: 10–22

Dinarello CA (1998) Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann NY Acad Sci 856: 1–11

Martinon F et al. (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10: 417–426

Martinon F et al. (2004) Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 14: 1929–1934

Kanneganti TD et al. (2006) Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440: 233–236

Mariathasan S et al. (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228–232

Petrilli V et al. (2007) Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 14: 1583–1589

Feldmeyer L et al. (2007) The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol 17: 1140–1145

O'Connor W Jr et al. (2003) Cutting edge: CIAS1/cryopyrin/PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory mediator with NF-kappa B suppressive properties. J Immunol 171: 6329–6333

Yu JW et al. (2006) Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ 13: 236–249

Chae JJ et al. (2006) The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 103: 9982–9987

Samuels J et al. (1998) Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 77: 268–297

Watanabe H et al. (2007) Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 127: 1956–1963

Sutterwala FS et al. (2006) Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24: 317–327

Pizarro TT et al. (2007) Cloning IL-1 and the birth of a new era in cytokine biology. J Immunol 178: 5411–5412

Dinarello CA (2007) Mutations in cryopyrin: bypassing roadblocks in the caspase 1 inflammasome for interleukin-1beta secretion and disease activity. Arthritis Rheum 56: 2817–2822

Lee SH et al. (2001) Cop, a caspase recruitment domain-containing protein and inhibitor of caspase-1 activation processing. J Biol Chem 276: 34495–34500

Humke EW et al. (2000) ICEBERG: a novel inhibitor of interleukin-1beta generation. Cell 103: 99–111

Annand RR et al. (1999) Caspase-1 (interleukin-1beta-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. Biochem J 342: 655–665

Stehlik C et al. (2003) The PAAD/PYRIN-only protein POP1/ASC2 is a modulator of ASC-mediated nuclear-factor-kappa B and pro-caspase-1 regulation. Biochem J 373: 101–113

Bedoya F et al. (2007) Pyrin-only protein 2 modulates NF-kappaB and disrupts ASC:CLR interactions. J Immunol 178: 3837–3845

Dinarello CA (2005) Blocking IL-1 in systemic inflammation. J Exp Med 201: 1355–1359

Kastner DL (2005) Hereditary periodic fever syndromes. Hematology Am Soc Hematol Educ Program 1: 74–81

McDermott MF (1999) Autosomal dominant recurrent fevers. Clinical and genetic aspects. Rev Rheum Engl Ed 66: 484–491

Hoffman HM et al. (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nat Genet 29: 301–305

Feldmann J et al. (2002) Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 71: 198–203

Aganna E et al. (2002) Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 46: 2445–2452

Gattorno M et al. (2007) Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 56: 3138–3148

Hawkins PN et al. (2004) Spectrum of clinical features in Muckle–Wells syndrome and response to anakinra. Arthritis Rheum 50: 607–612

Hoffman HM et al. (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364: 1779–1785

Brydges S et al. (2006) The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr Top Microbiol Immunol 305: 127–160

Shoham NG et al. (2003) Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA 100: 13501–13506

McDermott MF (2004) A common pathway in periodic fever syndromes. Trends Immunol 25: 457–460

So A et al. (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9: R28

McGonagle D et al.: Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum, in press

McGonagle D et al. (2006) A proposed classification of the immunological diseases. PLoS Med 3: e297

Pascual V et al. (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201: 1479–1486

Verbsky JW et al. (2004) Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31: 2071–2075

Colotta F et al. (1994) The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today 15: 562–566

Smith DE et al. (2003) The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18: 87–96

Lotito AP et al. (2007) Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis. J Rheumatol 34: 823–830

Maeno N et al. (2002) Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum 46: 2539–2541

Kawashima M et al. (2001) Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 44: 550–560

Choi JH et al. (2003) Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 30: 2422–2427

Bywaters EG (1971) Still's disease in the adult. Ann Rheum Dis 30: 121–133

Fitzgerald AA et al. (2005) Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 52: 1794–1803

Rudinskaya A et al. (2003) Successful treatment of a patient with refractory adult-onset still disease with anakinra. J Clin Rheumatol 9: 330–332

Kotter I et al.: Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum, in press

de Koning HD et al.: Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum, in press

Evans CH et al. (2005) Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA 102: 8698–8703

Stack JH et al. (2005) IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 175: 2630–2634

Wannamaker W et al. (2007) (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl- butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther 321: 509–516

Settas LD et al. (2007) Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J Clin Rheumatol 13: 219–220